Detalhe da pesquisa
1.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369355
2.
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Oncologist
; 23(2): 159-170, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29118268
3.
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Am J Hematol
; 98(4): E84-E87, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655608
4.
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Future Oncol
; 12(3): 293-302, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26785287
5.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 16(9): 1025-1036, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26234174
6.
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Am J Hematol
; 90(2): 97-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25345651
7.
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Invest New Drugs
; 31(4): 1023-34, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23397500
8.
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Haematologica
; 103(11): e514-e518, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794146
9.
Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
Am J Hematol
; 92(2): E17-E18, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27813149
10.
Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
Hematol Oncol Stem Cell Ther
; 15(2): 30-38, 2022 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33607101
11.
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
J Hematol Oncol
; 14(1): 133, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454540
12.
Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients.
Oncol Res
; 19(2): 93-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21302810
13.
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Blood Adv
; 3(4): 508-518, 2019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760466
14.
Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review.
Case Rep Hematol
; 2018: 3604298, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854498
15.
Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.
Oncotarget
; 9(5): 5703-5715, 2018 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29464028
16.
Therapies for acute myeloid leukemia: vosaroxin.
Onco Targets Ther
; 10: 3957-3963, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28860803
17.
Malignant adnexal masses in pregnancy.
Obstet Gynecol Clin North Am
; 32(4): 569-93, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16310673
18.
Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis.
Case Rep Hematol
; 2015: 826894, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26246921
19.
Pilot study of erlotinib in patients with acute myeloid leukemia.
Leuk Res
; 39(2): 170-2, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25498508
20.
Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
Leuk Res
; 77: 30-33, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30626561